Bispecific Antibodies: Clinical Trial Tracker
Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.
Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases.
The following companies and organisations have been mentioned in the report: